hotspot -WSS

hotspot

author：focus 2025-09-27 22:46:08 - browse：9

Eric Lander White House science office — Eric Lander resigned as President Biden’s science adviser, after a White House investigation found “credible evidence” that he had violated workplace conduct rules. Photo illustration: Alex Hogan/STAT; Source: Getty

WASHINGTON — An early sign that trouble was afoot in the White House science office came last November, when roughly a dozen of Eric Lander’s staff formed a “culture committee” aimed at improving morale.

The group’s first action, five aides told STAT, was to create a “word cloud” depicting the adjectives they most often used to describe the work environment at the White House Office of Science and Technology Policy. Of the dozens of words submitted, three in particular stood out: “hostile,” “siloed,” and “aggressive.”

Three months later, Lander resigned as President Biden’s science adviser, after Politico reported a White House investigation that found “credible evidence” that he had violated workplace conduct rules.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Pregnancy discrimination could be enabled by AI

entertainment

WSS

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

AI models in health care face new federal disclosure requirements

Biohaven protein

Pharma patents targeted by Biden in move to slash drug prices

SCOTUS to consider access to abortion pill mifepristone

FDA needs staff influx to meet gene therapy needs, Marks says

focus

hotspot

Wikipedia

Moonlake's readout produced a cash windfall. Risks remain

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Moonlake's readout produced a cash windfall. Risks remain

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

DIEP, the 'gold standard' of breast reconstruction, is under threat

Biohaven protein

Wildfire smoke exposes gaps in outdoor worker protections

Report: NIH

Duchenne breakthrough therapy leaves behind pioneering families

Teach medical students about patients with intellectual disabilities

leisure time

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Patients' immediate access to test results puts radiologists in a bind

STAT letters to the editor on burnt

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Adam's Biotech Scorecard: Do Sarepta's exon

hotspot

hotspot

entertainment

explore